The effects of esketamine on ED50 and BIS50 of propofol for loss of consciousness in patients of different ages

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062955

Enrollment

Unknown

Registered

2022-08-25

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anesthesia

Interventions

Group A:Intravenous esketamine

Group B:Intravenous esketamine

Group C:Intravenous esketamine

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective surgery under general anesthesia; 2. ASA I-II; 3. Age >=18 years; 4. BMI 18-25kg/m2; 5. All patients obtained written informed consent before surgery and volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Contraindication to propofol or esketamine; 2. Patients with uncontrolled or malignant hypertension, severe ischemic heart disease history, hyperthyroidism, a history of neuropsychiatric and chronic pain; 3. Patients with pregnant; 4. Abnormal liver and kidney function; 5. People with hearing impairment; 6. a history of drug and alcohol abuse.

Design outcomes

Primary

Measure	Time frame
median effective dosage (ED50);the BIS value (BIS50) at which 50% of patients lose consciousness;	—

Countries

China

Contacts

Public ContactNingkang Li

13629577087@163.com13629577087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026